Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol CR PK and Interaction Study
NCT02051387Phase 1Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Jan 2013
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cannabidiol in schizophrenia (7 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Plasma levels of cannabidiol at 10 days. Started Jan 2013; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02051387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051387.